AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
World Lung 2025 – pumitamig confirms its small-cell promise
Global data are in the same ballpark as Chinese results presented earlier this year.
BioNTech's take on iza-bren enters the clinic
The latest projects newly into human trials include BNT3212.
World Lung 2025 – crossing curves in lung cancer
Tolerability could decide first-line therapy in EGFRm disease.
Real transparency on FDA rejections
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Survival questions delay bemarituzumab
Ocular toxicities could be the reason.
World Lung 2025 – Ideaya challenges Zai Lab
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
World Lung 2025 – Bristol seeks PRMT5 biomarkers
A common mutation comes into play for PRMT5 inhibition.
